Centauri Therapeutics

Bacteria
#Centauri Therapeutics #FDA #Gram-negative bacteria

Gram-negative bacterial infection treatment gets QIDP status 

The US Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to a novel treatment of Gram-negative bacterial infections.  CTX-187, developed by immunotherapy company Centauri Therapeutics, is a novel immunotherapeutic approach to treat Gram-negative bacterial infections. It is hoped the therapeutic, currently in preclinical development ahead of… Read More

#News #Regulatory

Bacteria in Petri dishes
#Antimicrobial resistance (AMR) #Centauri Therapeutics #Gram-negative bacteria

Centauri raises financing with AMR Action Fund investment 

Immunotherapy company Centauri Therapeutics has extended its Series A financing to £30 million ($40.6 million) to support its lead candidate targeting Gram-negative bacterial infections.  The funding was extended thanks to a £6m ($8.1 million) investment from the AMR Action Fund. The financing from AMR Action Fund, the world’s largest venture capital… Read More

#Business & Investment #News

#Centauri Therapeutics #Gram-negative bacteria #Immunotherapy #Preclinical development

Bifunctional immunotherapy active against Gram-negative infections

A new paper has presented the first pre-clinical application of endogenous antibody recruitment to address multi-drug resistant Gram-negative infections. The study in The Journal of Immunology presents proof-of-concept data for CTX-09, an early molecule built on Centauri Therapeutics’ Alphamer platform.   In… Read More

#News

Bacteria
#Antimicrobials #Centauri Therapeutics #Funding #Immunotherapy

Centauri awarded £1m for immunotherapeutic technology

Immunotherapy developer Centauri Therapeutics has been awarded a £1 ($1.2) million grant by Pathways to Antimicrobial Clinical Efficacy (PACE), an initiative focused on early-stage antimicrobial drug and diagnostic discovery.   The funding will support the continued development of Centauri’s Alphamer technology, in this case targeting gram-negative bacteria including multi-drug resistant (MDR)… Read More

#Business & Investment #News